Steven Ratoff - Eagle Pharmaceuticals Independent Director
| EGRXDelisted Stock | USD 1.99 0.02 1.02% |
Director
Mr. Steven B. Ratoff is Independent Director of Eagle Pharmaceuticals, Inc., since March 2007. Mr. Ratoff has served as the chief executive officer of CM Systems LLC, a cloud based software company, since July 2018. Mr. Ratoff prior experience includes serving as a venture partner for ProQuest Investments from 2005 to 2013, as chief executive officer of Novadel Pharma, Inc., a specialty pharmaceutical company from 2010 to 2017, and as chief executive officer of CIMA Labs, Inc., a specialty pharmaceutical company acquired by Cephalon in 2004. In addition, Mr. Ratoff served as chief financial officer of the BrownForman Company from 1995 to 2001 since 2007.
| Age | 81 |
| Tenure | 17 years |
| Professional Marks | MBA |
| Phone | 201 326 5300 |
| Web | https://www.eagleus.com |
Eagle Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0663 % which means that it generated a profit of $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0488 %, meaning that it created $0.0488 on every $100 dollars invested by stockholders. Eagle Pharmaceuticals' management efficiency ratios could be used to measure how well Eagle Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Eagle Pharmaceuticals currently holds 62.47 M in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Eagle Pharmaceuticals has a current ratio of 1.74, which is within standard range for the sector. Debt can assist Eagle Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Eagle Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Eagle Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Eagle to invest in growth at high rates of return. When we think about Eagle Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 10 records | DIRECTOR Age | ||
| Celeste Clark | Prestige Brand Holdings | 67 | |
| James Jenness | Prestige Brand Holdings | 73 | |
| Philip CFA | Prestige Brand Holdings | N/A | |
| Sheila Hopkins | Prestige Brand Holdings | 64 | |
| Gary Costley | Prestige Brand Holdings | 55 | |
| YiChung Chao | Regencell Bioscience Holdings | 60 | |
| Daniel JD | Phibro Animal Health | 52 | |
| Natale Ricciardi | Prestige Brand Holdings | 71 | |
| John Byom | Prestige Brand Holdings | 66 | |
| Dawn Zier | Prestige Brand Holdings | 55 | |
Management Performance
| Return On Equity | 0.0488 | ||||
| Return On Asset | 0.0663 |
Eagle Pharmaceuticals Leadership Team
Elected by the shareholders, the Eagle Pharmaceuticals' board of directors comprises two types of representatives: Eagle Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eagle. The board's role is to monitor Eagle Pharmaceuticals' management team and ensure that shareholders' interests are well served. Eagle Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eagle Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Graves, Independent Director | ||
| Debra Hussain, Senior Commercial | ||
| Gaozhong Zhu, Senior Development | ||
| Reiner Nowak, Exec | ||
| Ryan Debski, General VP | ||
| John Kimmet, Ex Care | ||
| Daniel OConnor, Chief VP | ||
| Steven Ratoff, Independent Director | ||
| Scott Tarriff, CEO and President Director and Member of Executive Committee | ||
| Valentin MD, Senior Development | ||
| Brian Cahill, Chief Officer | ||
| Reed McClung, Executive Development |
Eagle Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Eagle Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0488 | ||||
| Return On Asset | 0.0663 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 82.05 M | ||||
| Shares Outstanding | 12.96 M | ||||
| Shares Owned By Insiders | 12.02 % | ||||
| Shares Owned By Institutions | 76.65 % | ||||
| Number Of Shares Shorted | 350.53 K | ||||
| Price To Earning | 40.52 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in Eagle Pink Sheet
If you are still planning to invest in Eagle Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eagle Pharmaceuticals' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |